Neogen Corp Files 8-K: Officer/Director Changes & Exhibits
Ticker: NEOG · Form: 8-K · Filed: Jan 7, 2025 · CIK: 711377
| Field | Detail |
|---|---|
| Company | Neogen Corp (NEOG) |
| Form Type | 8-K |
| Filed Date | Jan 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.16, $650,000, $2.5 million, $250 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, filings
Related Tickers: NEOG
TL;DR
NEOG 8-K: Leadership changes and financial updates filed Jan 7.
AI Summary
Neogen Corporation filed an 8-K on January 7, 2025, reporting events as of January 6, 2025. The filing indicates changes related to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
This filing signals potential shifts in Neogen's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: low — This is a routine corporate filing detailing standard board and officer changes and financial disclosures, not indicating immediate financial distress or significant operational disruption.
Key Players & Entities
- Neogen Corporation (company) — Registrant
- January 06, 2025 (date) — Date of earliest event reported
- January 7, 2025 (date) — Date of report
FAQ
What specific officer or director positions were affected by the events reported on January 6, 2025?
The filing indicates "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers" but does not specify the names or exact roles in the provided text.
Are the financial statements included in this filing preliminary or audited?
The filing states "Financial Statements and Exhibits" are included, but the nature (preliminary or audited) is not detailed in the provided text.
What is the primary business of Neogen Corporation?
Neogen Corporation is in the business of "IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES" as indicated by its Standard Industrial Classification code.
When is Neogen Corporation's fiscal year end?
Neogen Corporation's fiscal year ends on May 31st.
What is the SEC file number for Neogen Corporation?
The SEC file number for Neogen Corporation is 000-17988.
Filing Stats: 706 words · 3 min read · ~2 pages · Grade level 12.6 · Accepted 2025-01-07 16:03:29
Key Financial Figures
- $0.16 — nge on which registered Common Stock, $0.16 par value per share NEOG Nasdaq Glo
- $650,000 — n increased to reflect a base salary of $650,000, an annual incentive cash bonus opportu
- $2.5 million — -term incentive equity awards valued at $2.5 million. His increased compensation is effectiv
- $250 — h until December 31, 2025, at a rate of $250/hour. Mr. Jones also will be eligible f
Filing Documents
- neog-20250106.htm (8-K) — 42KB
- 0000950170-25-002820.txt ( ) — 178KB
- neog-20250106.xsd (EX-101.SCH) — 42KB
- neog-20250106_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEOGEN CORPORATION Date: January 7, 2025 By: /s/ Amy M. Rocklin Name: Amy M. Rocklin Title: Chief Legal & Compliance Officer, Corporate Secretary